- Home
- BTAI vs RNXT Comparison
BTAI vs RNXT Comparison
Compare BTAI & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTAI | RNXT |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.6M | 37.0M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BTAI | RNXT |
|---|---|---|
| Price | $1.24 | $0.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $23.25 | $8.00 |
| AVG Volume (30 Days) | ★ 1.3M | 473.6K |
| Earning Date | 03-27-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.63 | 20.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,123,000.00 |
| Revenue This Year | $141.28 | $2,995.35 |
| Revenue Next Year | $1,921.56 | $219.61 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2511.63 |
| 52 Week Low | $1.15 | $0.70 |
| 52 Week High | $8.08 | $1.45 |
Technical Indicators
Market Signals| Indicator | BTAI | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 36.32 | 48.46 |
| Support Level | N/A | $0.81 |
| Resistance Level | $1.77 | $1.07 |
| Average True Range (ATR) | 0.12 | 0.11 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 15.83 | 32.53 |
Price Performance
Historical ComparisonAbout BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.